Guggenheim lowered the firm’s price target on Illumina (ILMN) to $122 from $150 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for several companies in its Diagnostics and Life Sciences Tools coverage to reflect recent updates from the companies after meetings with management teams.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Corvex’s Keith Meister to join Illumina’s board, WSJ reports
- Illumina elects Dr. Scott Gottlieb as Chair, Keith Meister to join board
- No change to Illumina story amid board changes, ‘eventful’ 24 hours, says BofA
- Activist Investors Seize More Control of Illumina Amid Weakness
- Illumina’s Strategic Cost-Saving Measures and Resilience Amid Market Challenges Support Buy Rating